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Primary immunodeficiency diseases (PIDs) 
are a group of disorders with defects in the 
development or function (or both) of the 
immune system. Most PIDs originate from 
mutations in single genes, but polygenic 
forms do occur.1 The global prevalence of 
PIDs varies between 0.3 and 12 per 100 000 
population, and is higher in areas with high 
rates of consanguinity.2 The prevalence in 
South Africa is unknown, but according 
to prevalence data reported from the PID 
register,3 these diseases are either missed 
or not reported. The possible reasons for 
under-diagnosis are that patients presenting 
with recurrent, persistent, severe or even 
unusual infections are treated without 
investigating the underlying cause, or 
the diagnosis is missed in the face of the 
overwhelming burden of similar clinical 
presentations of infectious diseases such as 
HIV and tuberculosis.  
Early diagnosis is important as therapeutic 
options are available to treat and prevent 
long-term sequelae such as bronchiectasis, 
which will improve quality of life and 
decrease mortality.4 Basic laboratory 
assays to screen for PIDs are available 
throughout South Africa but the threshold 
for investigation among healthcare workers 
is high. This review aims to increase the 
clinical suspicion of PIDs in South Africa 
and provide an approach to the diagnosis 
and management.
Warning signs 
PID should be strongly suspected in an 
individual who has a family history of the 
disease. Warning signs are failure to thrive 
or a history of infections that are Severe 
(requiring intravenous antibiotics and 
hospital admission), Persistent (difficult to 
treat with standard regimens), caused by 
Unusual infective organisms (opportunistic 
pathogens) and Recurrent (repeated 
infection at the same site or with the same 
organism). These infective features have 
been given the acronym SPUR. PID should 
also be suspected in individuals with early-
onset autoimmune diseases or malignancy.5
Presentation may occur soon after birth or 
may be delayed, depending on the immune 
defect.1 Typically, T lymphocyte and 
combined defects are severe and patients 
present before 6 months of age. Patients 
with antibody deficiencies generally present 
after 6 months of age when passive maternal 
antibodies have declined, or often much 
later in life. Patients with complement and 
phagocytic defects frequently have a delayed 
presentation.6
Major immune defects and 
their associated infections1,7
The immune system comprises the innate 
(complement and phagocytes) and adaptive 
responses (T and B lymphocytes). The 
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complement system recruits phagocytes, 
enhances phagocytosis or directly lyses 
bacteria. Phagocytes (neutrophils, monocytes, 
macrophages and dendritic cells) engulf 
extracellular pathogens and destroy them by 
intracellular killing mechanisms. If phagocytes 
cannot kill the pathogen, foreign pathogen 
peptides are presented to T lymphocytes. 
Intracellular pathogens (e.g. viruses) activate 
CD8+ cytotoxic T lymphocytes to kill the 
infected cell. Extracellular pathogens (e.g. most 
bacteria) activate CD4+ T helper lymphocytes, 
which help B cells to produce antibody. CD4+ 
T lymphocyte defects therefore result in a 
picture of both T and B cell dysfunction – a 
Table 1. Infections commonly associated with the major immune defects
Immune defect Bacteria Virus Fungi Protozoa
Complement 
deficiency
Neisseria spp.,
streptococci,
Haemophilus influenzae, 
other encapsulated bacteria
- - -
Phagocytic defects Staphylococcus aureus, Pseudomonas 
aeruginosa, non-tuberculous 
mycobacteria 
- Candida spp., Aspergillus 
spp.
-
Antibody deficiency Streptococci, staphylococci, 
Haemophilus influenzae, Moraxella 
catarrhalis, Pseudomonas aeruginosa, 
Mycoplasma pneumoniae
Enteroviruses - Giardia lamblia
T cell defects Similar to antibody deficiencies but 
also includes the intracellular bacteria 
Salmonella typhi, Listeria monocytogenes 
and non-tuberculous  mycobacteria
All viruses Candida spp., Aspergillus 
spp., Cryptococcus 
neoformans,
Histoplasma capsulatum
Pneumocystis jirovecii, 
Toxoplasma gondii,
Cryptosporidium 
parvum
Modified from referance 10.
Table 2. Classification of PIDs 
PID group Associated features Example
1. Combined immunodeficiencies Failure to clear live vaccines, 
early-onset infections (Pneumocystis jirovecii, viral 
or bacterial), persistent Candida infections
Severe combined 
immunodeficiencies (SCIDs)
2.  Well-defined syndromes with 
immunodeficiency
Distinct clinical features in addition to immune deficiency DiGeorge anomaly
3. Predominantly antibody deficiency Decreased antibody levels with recurrent infections, especially 
sinopulmonary (encapsulated bacteria) and gastrointestinal 
infections (enterovirus and Giardia)
Severe reduction in at least two 
serum immunoglobulin isotypes 
with normal or low numbers of 
B cells, e.g. combined variable 
immunodeficiency disorders 
(CVIDs)
4. Diseases of immune dysregulation Significant autoimmune manifestations X-linked lymphoproliferative 
disorders 
5.  Congenital defects of phagocyte 
number, function, or both
Recurrent and severe bacterial, mycobacterial and fungal 
infections (respiratory, cutaneous) or deep-seated abscesses
X-linked chronic granulomatous 
disease
6. Defects in innate immunity Recurrent bacterial, viral (in particular herpes simplex), and 
fungal (often Candida) infections
Chronic mucocutaneous candidiasis
7. Auto-inflammatory disorders Recurrent fever, rash, urticaria Defects affecting the inflammasome, 
e.g. hyper-IgD syndrome
8. Complement deficiencies Recurrent Neisseria spp. infections Late complement component 
deficiency
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combined deficiency similar to the features 
seen in HIV infection.  
Infections commonly associated with the 
major immune defects are given in Table 1. 
The type of infection can assist the clinician 
in recognising particular syndromes and in 
directing the laboratory investigations. 
Classification of PID
The Expert Committee of the International 
Union of Immunological Societies updated 
the classification of PIDs in 2011.8  PIDs can 
be classified into 8 major groups (Table 2).
Differential diagnosis6
The differential diagnosis includes causes 
of secondary immune deficiency such as 
chronic infections, malnutrition, use of 
immunosuppressive drugs, splenectomy, 
malignancy and burns.
Diagnosis 
The most critical part of the medical 
evaluation is obtaining a good history and 
performing a physical examination, as the 
site and types of infections may provide 
clues about the underlying defect.  
Laboratory investigations and 
their clinical significance
A stepwise approach should be employed 
when investigating a patient for a possible 
PID.7 
Step 1
•	 Exclude causes for secondary immune 
defects, e.g. HIV or Mycobacterium 
tuberculosis infection, or do a sweat test 
to exclude cystic fibrosis. 
•	 Full blood and differential count with 
peripheral smear: This is used to assess 
the white cell counts and to identify 
specific morphological features. The 
following features may be relevant to PID:
•	 Neutropenia – may be congenital, 
cyclic or occur in aplastic anaemia.
•	 Lymphopenia – suggests a T cell 
disorder because approximately 70% 
of circulating lymphocytes are T cells.
•	 Leukocytosis that persists between 
infections may occur in leukocyte 
adhesion deficiency (LAD).
•	 Thrombocytopenia and the presence 
of microthrombocytes in male infants 
suggest Wiskott-Aldrich syndrome.
•	 Anaemia may suggest autoimmune 
haemolytic anaemia, which may 
occur in common variable immune 
deficiency (CVID), or anaemia of 
chronic disease. 
•	 A peripheral blood smear should 
be examined for features of asplenia 
or impaired splenic function. 
Granulocytes may have morphological 
abnormalities (e.g. giant granules in 
Chédiak-Higashi syndrome).
•	 Absent staining of myeloid cell 
granules shows myeloperoxidase 
deficiency.
•	 Quantitative immunoglobulins for 
immunoglobulin M (IgM), IgG, IgA 
and IgE. IgD is not routinely measured. 
Antibody deficiencies account for the 
majority of reported cases of PID. 
Selective IgA is the most common 
PID, and the majority of these patients 
are asymptomatic. IgA is absent in 
selective IgA deficiency. Low levels 
of immunoglobulins with normal B 
lymphocyte numbers suggest CVID. 
High IgM levels with low IgG/IgA/IgE 
occur in class switch recombination 
deficiencies. High IgE levels are 
characteristic of the hyper IgE syndrome 
but also found in Omenn syndrome, 
which is a combined immune deficiency.
•	 Complement levels are evaluated by 
the CH50 and AH50 – screening tests 
that assess the ability of the classic 
and alternative complement pathways 
respectively to haemolyse red blood cells. 
Reduced haemolytic activity is noted in 
complement factor deficiencies, but also 
during infections or immune complex 
diseases. Alternatively, complement 
factors can be directly measured.
•	 Quantitation of lymphocytes, which is 
the enumeration of B lymphocytes, T 
lymphocytes and natural killer (NK) 
cells by flow cytometry. Absence of B 
cells with normal T cells and NK cells is 
in keeping with agammaglobulinaemia, 
while reduced T cells are found in severe 
combined immunodeficiency syndrome 
(SCID). 
These simple tests are usually sufficient 
to make the diagnosis of a PID and to 
commence therapy or refer the patient. 
If the above-mentioned tests are normal, 
and suspicion of PID remains, functional 
assessments (step 2) should be undertaken.
Step 2
•	 Functional analysis of B lymphocyte 
and IgG subclasses. Analyse antibody 
responses to protein antigens (e.g. 
antibody response to tetanus vaccine) 
and polysaccharide antigens (e.g. 
antibody response to Streptococcus 
pneumoniae polysaccharide vaccine). 
If the antibody response to a vaccine 
antigen is low, the patient should 
be vaccinated to ensure appropriate 
exposure, and antibody levels should 
be retested 4 weeks after vaccination. 
IgG subclasses should only be requested 
if total IgG is normal, if IgA is absent, 
hyper IgE syndrome is suspected or 
antibody responses to vaccines are poor. 
•	 Functional analysis of T lymphocytes.  T 
lymphocyte function can be measured 
by analysing cytokine production 
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or  proliferation. The Mantoux test 
is an in vivo delayed hypersensitivity 
response to purified peptide derivative. 
T lymphocytes proliferate in response 
to antigens and mitogens. Tests for 
function require viable cells and must 
reach the laboratory within 6 - 12 hours.
•	 Functional analysis of the innate 
immune system, including phagocytic 
defects. Chemotaxis (ability of 
neutrophils to migrate to the site of 
infection), phagocytosis (engulfment of 
foreign pathogens), and the oxidative 
burst (intracellular killing) functions 
of neutrophils and monocytes can be 
assessed.
Step 3
Molecular tests are performed to confirm 
the diagnosis of specific defects. This will 
be guided by results of tests performed in 
steps 1 and 2. For example, identification of 
a mutation in Bruton’s tyrosine kinase gene 
is used to confirm the diagnosis of X-linked 
agammaglobulinaemia. 
Neonatal screening for severe 
primary immunodeficiency
Severe combined immunodeficiency is a 
medical emergency requiring urgent bone 
marrow transplantation and avoidance of 
live vaccines, such as the oral polio and 
bacille Calmette-Guérin (BCG), routinely 
given at birth. The total lymphocyte 
count may be used to screen for severe 
combined immunodeficiency. While 
routine screening is not practised in South 
Africa, it should be essential for any child 
born to a mother who has previously lost 
an infant owing to an infectious cause. 
Neonatal screening for T lymphopenia by 
molecular methods from dried blood spots 
is available in some areas of the USA.9
General principles of 
management1
Supportive
•	 Prevent infections with prophylactic 
antibiotics and/or antifungals. The choice of 
antimicrobial will depend on the immune 
defect. Penicillin is commonly used for 
late complement factor deficiencies, co-
trimoxazole and itraconazole for chronic 
granulomatous disease and co-trimoxazole 
for T cell defects.
•	 Treat infections promptly and aggressively. 
Antibiotics should be prescribed in 
accordance with microbiological culture 
and drug sensitivity testing.
•	 Give nutritional support, as micro 
nutrients such as zinc, vitamin D and 
vitamin A are required for immune 
function. 
•	 Use only irradiated blood products for 
transfusions to prevent possible graft 
versus host disease.
•	 Avoid the use of live attenuated 
vaccines, e.g. oral polio, BCG, measles, 
mumps, rubella, varicella or rotavirus, 
in any patient with T cell or severe 
immunodeficiency to prevent vaccine-
associated infections. Live vaccines 
should be avoided whenever there is a 
family history of severe PID.  
•	 Do a chest X-ray to exclude the presence 
of chronic lung disease.
•	 Notify patients on the South African PID 
register.
•	 Refer the patient for specific treatment. 
The laboratory can assist with referral 
details.
Specific
•	 B lymphocyte and antibody deficiencies: 
Lifelong intravenous or subcutaneous 
immunoglobulin supplementation.
•	 SCID: Haematopoietic stem cell 
transplant from an HLA identical 
sibling. Gene therapy has been shown to 
be successful, as immune reconstitution 
was achieved in children with SCID. 
However, it is not yet routinely used 
as a therapeutic modality as it caused 
lymphoma in some recipients.
•	 Phagocytic defects: Interferon gamma 
supplementation.
In a nutshell
•	 PIDs are caused by genetic defects in the immune system.
•	 Suspect PID in any individual with SPUR (Severe, Persistent, Unusual and Recurrent infec-
tions).
•	 PIDs cause severe morbidity and irreversible infection-related pathology, which can be pre-
vented by early diagnosis.
•	 Simple screening assays to assist with diagnosis are available. Screening tests include a full 
blood count and differential, enumeration of B, T and natural killer (NK) cells, quantitation 
of immunoglobulins and measurement of complement components. 
•	 Laboratory work-up should be guided by the history and examination. 
•	 Appropriate therapeutic options to treat, prevent organ pathology and improve quality of 
life are available.
•	 Antibody deficiencies are the most common PIDs and are easily treated with immuno-
globulin supplementation.
•	 Avoid live vaccines in patients with severe PIDs.
•	 Treat infections aggressively and use prophylactic antimicrobials to prevent new infections.
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